TY  - JOUR
PY  - 2009//
TI  - Immunochemotherapy with interferon-α, interleukin-2, 5-fluorouracil, and cimetidine for patients with advanced renal cell carcinoma
JO  - Journal of Nara Medical Association
A1  - Miyake, M.
A1  - Fujimoto, K.
A1  - Tanaka, M.
A1  - Hirao, Y.
A1  - Uemura, H.
A1  - Otani, T.
A1  - Yoshii, M.
SP  - 37
EP  - 47
VL  - 60
IS  - 1-2
N2  - Introduction. We prospectively evaluated the efficacy and safety of immunochemotherapy using INF-α, IL-2, 5-fluorouracil (5-FU), and cimetidine in patients with metastatic renal cell carcinoma (RCC). Patients and Methods. Twenty-two patients with metastatic RCC were given 4 weeks of initial therapy consisting of IFN-α- (3-6x10 6 IU/day 3 times/week), IL-2 (0.7-1.4x10 6 JRU/day for 5 consecutive days/week), 5-FU (150 mg/m2/day for 5 consecutive days/week), and Cimetidine (800 mg/day), followed by maintenance therapy with IFN-α, IL-2, and Cimetidine. The response rate, overall and progression-free survivals, and adverse events were analyzed. <br><br>RESULTS. The median periods of therapy and follow-up were 4.4 months (range: 0.4-33) and 28.8 months (range: 1-65), respectively. The early anti-tumor effect was a complete response in one (4.5%), a partial response in 3 (13.6%), no change in 9 (40.9%), and progressive disease in 9 (40.9%). The 2-year progression-free and overall survival rates were 31% and 76%, respectively. The overall survival of cytokine-naïve group was higher than that of cytokine-resistant group (p<0.032). Adverse events of grade ≤3 occurred in 5 patients, and 9 discontinued this therapy due to adverse events. <br><br>CONCLUSION. The present regimen had a low response rate despite the high incidence of adverse events and should be limited to patients with cytokine-naïve metastatic RCC.<p /> <p>Language: en</p>
LA  - en
SN  - 1345-0069
UR  - http://dx.doi.org/
ID  - ref1
ER  -